Novo Nordisk, Microsoft-backed OpenAI Partner to Accelerate Drug Development With AI Integration

MT Newswires Live16:26

Novo Nordisk (NVO) said Tuesday it has formed a strategic partnership with Microsoft (MSFT)-backed OpenAI to deploy advanced AI across its operations, aiming to accelerate drug discovery and improve efficiency from research through commercialization.

The partnership will use AI to analyze complex data, identify promising drug candidates, and speed development timelines, while maintaining strict data governance and human oversight to ensure ethical and compliant use.

Novo Nordisk said the initiative includes upskilling its workforce and expanding AI across operations, with pilot programs in key units and full integration expected by the end of 2026.

Financial terms of the agreement were not disclosed, it added.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment